China's Aging Population Spurs OTC Sales, Looks For More Options
This article was originally published in The Tan Sheet
China's over-the-counter drug market grew more than 30 percent from 2007 to 2009 to more than RMB 90 billion ($13 billion), according to health care market intelligence provider IMS Health
You may also be interested in...
China's latest draft guideline on good manufacturing practices for drugs offers clarity on a few key points but still leaves huge gaps that need to be filled
China aims to upgrade supervision of its entire health care sector with an array of regulatory changes for pharmaceuticals and medical devices likely this year, including good manufacturing practice guidelines, according to a leading lawyer in the area of China's life sciences-related issues and legislation
Bayer closes its $157 million acquisition of part of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co.'s OTC assets, the firms say July 3. Bayer gained the Chinese firm compound pseudoephedrine hydrochloride tablets, which analysts expect to produce $48 million in sales this year. Bayer will also pay a $24 million bonus at the end of the year as part of the deal (1"The Tan Sheet" Oct. 30, 2006, p. 9)...